HPLC vs Mass Spectrometry: How Research Peptides Are Verified

HPLC and mass spectrometry answer two different questions about a research peptide. HPLC (usually reversed-phase HPLC on a C18 column with a water/acetonitrile-TFA gradient) separates the components of a sample and reports how pure the target peak is, expressed as a percentage of total UV absorbance at 214 or 220 nm. Mass spectrometry (typically ESI-MS or MALDI-TOF) measures the molecular mass of the peptide in the sample and reports whether the observed mass matches the expected mass of the intended sequence — it confirms identity. Neither method alone qualifies a peptide vial for use: HPLC without mass spectrometry cannot rule out that a pure peak is the wrong molecule, and mass spectrometry without HPLC cannot report the relative amount of impurities alongside the correct molecule.

Updated August 30, 2026 · Peptide Research Guides · ~10 min read

What Each Method Actually Measures

HPLC and mass spectrometry are often listed together on a research-peptide Certificate of Analysis, and the two acronyms tend to blur into a single “analytical testing” line item. They are not measuring the same thing.

Method	What it measures	What it does not settle on its own
HPLC (RP-HPLC)	Relative purity of the sample by UV absorbance at 214 or 220 nm, expressed as % area of the main peak vs total area.	Whether the main peak is actually the intended peptide sequence.
Mass spectrometry (ESI-MS or MALDI-TOF)	Molecular mass of ionized species in the sample, reported as observed [M+H]⁺ or [M+nH]ⁿ⁺ matched against the expected mass of the sequence.	The relative amount of the target peptide versus other species that ionize at different masses.
LC-MS (HPLC coupled to MS)	Both, in one experiment: components are separated first, then each peak is mass-identified as it elutes.	Nothing about the peptide itself, but it is more expensive and less common at the research-supply COA level than the separate HPLC + MS combination.

How HPLC Reports Peptide Purity

The reversed-phase HPLC (RP-HPLC) method used across the peptide-supply industry runs the reconstituted sample through a hydrophobic stationary phase (typically octadecyl-silica, C18) with a water/acetonitrile mobile phase acidified with 0.1% trifluoroacetic acid (TFA) — occasionally 0.1% formic acid where the downstream method needs a volatile mobile phase. Peptides elute in order of relative hydrophobicity, and the detector at 214 or 220 nm records absorbance by the peptide backbone amide bond as each species crosses the flow cell. The purity number that appears on a COA is the integrated area of the target peak divided by the total integrated area, expressed as a percentage.

A few implications follow from that definition:

The number is a relative percentage, not an absolute count of molecules. It compares peak areas within one chromatogram, using an assay where the response factor for peptide-bond absorbance at 214 nm is reasonably conserved across peptides but not identical.
Impurities that do not absorb at the detector wavelength are invisible to that assay. Common examples include residual counterion (TFA or acetate) and residual solvent; separate tests report those.
The same peptide can give different purity numbers on different methods. A gradient that co-elutes the target peak with a close-eluting impurity will report a higher purity than a more discriminating method that resolves them. Reputable COAs describe the method and the wavelength alongside the number.
Purity is not identity. A single sharp 99% peak can still be the wrong molecule, or the right molecule with an unexpected modification, if HPLC is the only assay used.

How Mass Spectrometry Reports Peptide Identity

Mass spectrometry ionizes the peptide (by electrospray in ESI-MS, or by laser desorption from a MALDI matrix in MALDI-TOF), separates the resulting ions by their mass-to-charge ratio, and reports the observed mass of each ion. For a peptide, the analyst compares the observed [M+H]⁺ or [M+nH]ⁿ⁺ mass against the theoretical average or monoisotopic mass of the intended sequence:

ESI-MS tends to produce multiply-charged ions (2+, 3+, 4+ and so on) for peptides above a few thousand daltons and is the routine method for larger research peptides. The deconvoluted mass is the reported value.
MALDI-TOF tends to produce singly-charged [M+H]⁺ ions and is common for shorter and mid-length peptides, with the observed mass reported directly.

The identity check is a match, not a range. A peptide whose theoretical average mass is 4,113.6 Da (semaglutide) should be observed within a small delta of that value on a well-calibrated instrument. A deviation of tens or hundreds of daltons points to a real problem — a truncation, an incorrect residue, a missing or extra modification (for example a missing fatty-diacid modification will drop the mass by hundreds of daltons), a different counterion form, or the wrong molecule entirely.

Why Both HPLC and Mass Spectrometry Are Required

Neither method on its own qualifies a research-peptide vial for use in an experiment.

HPLC without MS can report a beautiful 99% peak that is 99% of the wrong molecule. If synthesis went off-track and produced a homogeneous but incorrect sequence, RP-HPLC will not catch it — the wrong peptide can still elute as a single peak and read out as high purity. Only mass identification exposes the mismatch.
MS without HPLC can confirm that the intended sequence is present in the sample without saying how much of the sample it is. A vial that contains 40% target peptide and 60% synthesis-related impurities can still produce a strong signal at the expected mass; mass spectrometry alone cannot report the relative purity.
Combined, they answer both questions. HPLC reports the % area of the main peak; MS confirms that peak (or the deconvoluted mass of the sample) matches the expected mass of the intended sequence. Together they establish both identity and purity, which is what any downstream assay needs.

A research-peptide COA that reports HPLC alone or MS alone is missing half of the verification. Reputable research-supply COAs report both, alongside appearance, water content, counterion, and (for cell-based work) an endotoxin figure. See How to Read a Peptide Certificate of Analysis for a section-by-section walkthrough.

Reading an HPLC Result on a COA

Four data points are worth looking at whenever HPLC data appears on a peptide COA:

Method described. Column chemistry (usually C18), mobile-phase composition (water/acetonitrile with a small percentage of TFA or formic acid), gradient, flow rate, and detection wavelength.
Detection wavelength. 214 nm and 220 nm are the standard peptide-backbone wavelengths; 254 nm reports chromophores such as aromatic residues but understates purity for many peptides.
Chromatogram, not just a number. A trace with a single sharp main peak and no significant shoulder is what a high purity number should look like. A chromatogram that shows a large main peak with a merged shoulder that has been reported as a single peak inflates the purity number.
The reported purity itself. Research-grade peptides commonly target ≥95% by area; ≥98% is common for high-quality vendors, and sensitive receptor-binding or cell-based assays often require ≥98%. The target purity depends on the downstream assay, and it is a decision the researcher makes against the actual COA, not against a universal number.

Reading a Mass Spectrometry Result on a COA

Three data points are worth looking at whenever mass-spec data appears on a peptide COA:

Method described. ESI-MS or MALDI-TOF, positive- or negative-ion mode, and the calibration reference.
Observed vs expected mass. The observed [M+H]⁺ or deconvoluted [M] should match the theoretical average or monoisotopic mass of the intended sequence within the resolving power of the instrument — typically well under 1 Da for a high-resolution instrument and a small handful of daltons for a routine MALDI-TOF instrument on a mid-sized peptide.
Whether modifications are accounted for. Fatty-acid conjugation, N-terminal acetylation, PEG linkers, and phosphorylation each shift the expected mass by a defined amount. A COA that reports a mass matching the unmodified backbone for a peptide that is meant to carry a C18 or C20 fatty diacid indicates the modification is missing.

Common Misconceptions About Peptide Analytical Testing

“HPLC and mass spec measure the same thing.” They do not. HPLC reports relative purity by UV absorbance; MS reports molecular mass. Each answers half of the verification question.
“A 99% HPLC number proves the vial is the correct peptide.” It does not, on its own. A pure peak can still be the wrong molecule.
“A matching mass proves the vial is pure.” It does not, on its own. A matching mass proves the correct molecule is present in the sample and says nothing quantitative about how much of the sample it is.
“Higher purity is always better.” Higher purity is better up to the point where the downstream assay needs it. A ≥95% peptide can be perfectly adequate for one experiment and inadequate for another; the right target is set by the assay, not by a universal number.
“Third-party COAs and in-house COAs are equivalent.” Only if the third party is genuinely independent and the batch is reconciled to the vial the researcher is holding. See How to Read a Peptide COA for the batch reconciliation check.

Key Takeaways

HPLC (usually RP-HPLC on a C18 column with a water/acetonitrile-TFA gradient, detection at 214 or 220 nm) reports relative purity as % area of the main peak.
Mass spectrometry (ESI-MS or MALDI-TOF) reports the molecular mass of the peptide, which the analyst matches against the expected mass of the intended sequence to confirm identity.
HPLC without MS cannot rule out that a pure peak is the wrong molecule.
MS without HPLC cannot report how much of the sample is the correct molecule.
A trustworthy research-peptide COA reports both, with the method described, the wavelength stated, and the observed mass listed against the expected mass.

Frequently Asked Questions

What is the difference between HPLC and mass spectrometry for peptides?

HPLC separates the components of a peptide sample and reports how much of the total UV signal is the target peak, expressed as a percentage — a measure of relative purity. Mass spectrometry measures the molecular mass of the peptide in the sample and reports whether that mass matches the expected mass of the intended sequence — a measure of identity. Purity and identity are two different questions and each needs its own assay.

Is mass spectrometry more accurate than HPLC?

The question is not really about accuracy; the two methods report different quantities. Mass spectrometry answers a question HPLC cannot (identity), and HPLC answers a question mass spectrometry cannot (relative purity in a mixture). A COA that reports both is more informative than a COA that reports only one, regardless of which one is missing.

What HPLC method is used for peptide purity?

The industry-standard method is reversed-phase HPLC on a C18 column with a linear water/acetonitrile gradient acidified with 0.1% trifluoroacetic acid (TFA); occasionally 0.1% formic acid is used where a volatile buffer is needed downstream. Detection is at 214 or 220 nm to capture the peptide-bond amide absorbance. Purity is reported as the % area of the main peak versus total area at the stated wavelength.

What is the difference between ESI-MS and MALDI-TOF for peptides?

Both ionize the peptide and separate ions by mass-to-charge ratio. ESI-MS typically produces multiply-charged ions and is common for larger peptides; the reported mass is deconvoluted from the observed charge states. MALDI-TOF typically produces singly-charged [M+H]⁺ ions from a laser-desorbed matrix and is common for shorter and mid-length peptides. Either method can confirm identity by matching the observed mass to the expected mass of the sequence.

What does 98% purity mean on a peptide COA?

It means that in the HPLC chromatogram used to generate the COA, the target peak accounts for approximately 98% of the total peak area at the stated detection wavelength. It does not mean 98% of every molecule in the vial by count, and it does not say anything about the identity of the main peak on its own — that comes from the mass-spectrometry portion of the report.

Can HPLC alone confirm a peptide’s identity?

No. HPLC reports how pure the main peak is. It cannot on its own confirm that the main peak is the intended peptide. A synthesis error that produces a homogeneous but incorrect sequence can still give a high HPLC purity number. Identity confirmation requires mass spectrometry.

Why is 214 nm used for peptide HPLC?

Peptide bonds absorb strongly in the far-UV around 210–220 nm because of the n→π* transition of the amide carbonyl. Detection at 214 or 220 nm therefore captures the peptide backbone rather than only aromatic side chains, which makes the % area on a peptide chromatogram a reasonably faithful indicator of relative peptide content. 254 nm undercounts purity for peptides without aromatic residues.

Do research-supply peptide COAs need both HPLC and MS data?

A trustworthy research-supply COA reports both. HPLC establishes purity; MS establishes identity. A COA that reports only one is not a complete verification of the peptide, and a downstream assay that is sensitive to either purity or identity may fail silently on incomplete analytical data.

References

Mant CT, Chen Y, Yan Z, et al. HPLC analysis and purification of peptides. In: Methods in Molecular Biology, vol. 386. Humana Press. Peer-reviewed methods overview of reversed-phase HPLC for peptides. Indexed at PubMed.
Aguilar M-I. Reversed-Phase High-Performance Liquid Chromatography of Peptides and Proteins. In: HPLC of Peptides and Proteins: Methods and Protocols. Humana Press, 2004. Chapter on RP-HPLC theory and practice.
Fenn JB, Mann M, Meng CK, Wong SF, Whitehouse CM. Electrospray ionization for mass spectrometry of large biomolecules. Science 1989;246(4926):64–71. Original description of ESI-MS. DOI: 10.1126/science.2675315.
Karas M, Hillenkamp F. Laser desorption ionization of proteins with molecular masses exceeding 10,000 daltons. Anal Chem 1988;60(20):2299–301. Original MALDI method paper. DOI: 10.1021/ac00171a028.
U.S. Pharmacopeia. General Chapter <1225> Validation of Compendial Procedures and General Chapter <621> Chromatography. usp.org.
ICH Q6B. Specifications: Test Procedures and Acceptance Criteria for Biotechnological / Biological Products. International Council for Harmonisation.

Research use disclaimer. All peptides sold by AppealLabs are labelled FOR RESEARCH USE ONLY · NOT FOR HUMAN CONSUMPTION. This page describes analytical methods used to verify research peptides and is educational content, not medical or regulatory advice.